Drug Profile
Autologous adipose-derived mesenchymal stem cell therapy - AbelZeta Pharma
Alternative Names: Adipose-derived mesenchymal progenitor cell therapy - AbelZeta Pharma; Autologous haMPC therapy - AbelZeta Pharma; ReJoin® autologous Human Adipose-derived Mesenchymal Progenitor Cell - AbelZeta PharmaLatest Information Update: 27 Nov 2023
Price :
$50
*
At a glance
- Originator Cellular Biomedicine Group; Shanghai Jiao Tong University
- Developer AbelZeta Pharma; Shanghai Jiao Tong University
- Class Antiasthmatics; Antirheumatics; Mesenchymal stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Cartilage disorders; Osteoarthritis
- No development reported Asthma; Chronic obstructive pulmonary disease
Most Recent Events
- 20 Nov 2023 Cellular Biomedicine Group is now called AbelZeta Pharma
- 12 Sep 2019 NMPA accepts an IND application for a prospective phase II trial in Osteoarthritis (of the knee) in China (Intra-articular)
- 12 Sep 2019 Cellular Biomedicine Group plans a phase II trial in Osteoarthritis (of the knee) in China (Intra-articular)